# Advancing Reperfusion Therapy for Ischemic Stroke: Safety and Efficacy of Anakinra for Futile Reperfusion Following Endovascular Treatment in Patients With Acute Ischemic Stroke

> **NCT07423975** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Beijing Tiantan Hospital** · enrollment: 159 (estimated)

## Conditions studied

- Stroke Acute
- Endovascular Treatment

## Interventions

- **DRUG:** High-dose Anakinra
- **DRUG:** Low-dose Anakinra
- **OTHER:** Standard medical treatment

## Key facts

- **NCT ID:** NCT07423975
- **Lead sponsor:** Beijing Tiantan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-01
- **Primary completion:** 2026-09-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 159 (ESTIMATED)
- **Last updated:** 2026-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07423975

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07423975, "Advancing Reperfusion Therapy for Ischemic Stroke: Safety and Efficacy of Anakinra for Futile Reperfusion Following Endovascular Treatment in Patients With Acute Ischemic Stroke". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07423975. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*